Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
Hippius
H
H
Ackenheil
M
M
Müller-Spahn
F
F
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001058:Apomorphine; D004361:Drug Tolerance; D004700:Endocrine System Diseases / Q000139:chemically induced*; D004723:Endorphins / Q000097:blood; D005260:Female; D014644:Genetic Variation; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007031:Hypothalamus / Q000503:physiopathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced*; D009638:Norepinephrine / Q000097:blood; D011388:Prolactin / Q000097:blood / Q000134:cerebrospinal fluid; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D011954:Receptors, Dopamine / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D013972:Thyrotropin / Q000097:blood; D001615:beta-Endorphin
D014150:Antipsychotic Agents; D004723:Endorphins; D011942:Receptors, Adrenergic, alpha; D011954:Receptors, Dopamine; D008734:Methoxyhydroxyphenylglycol; D001615:beta-Endorphin; D011388:Prolactin; D007986:Luteinizing Hormone; D013972:Thyrotropin; D001058:Apomorphine; D006854:Hydrocortisone; D009638:Norepinephrine; D006719:Homovanillic Acid